[go: up one dir, main page]

AR030382A1 - Formulacion oral de un inhibidor de ciclooxigenasa-2 de fusion rapida - Google Patents

Formulacion oral de un inhibidor de ciclooxigenasa-2 de fusion rapida

Info

Publication number
AR030382A1
AR030382A1 ARP010103961A ARP010103961A AR030382A1 AR 030382 A1 AR030382 A1 AR 030382A1 AR P010103961 A ARP010103961 A AR P010103961A AR P010103961 A ARP010103961 A AR P010103961A AR 030382 A1 AR030382 A1 AR 030382A1
Authority
AR
Argentina
Prior art keywords
drug
agent
inhibitor
cyclloxygenasa
granules
Prior art date
Application number
ARP010103961A
Other languages
English (en)
Inventor
Trang T Le
Tugrul T Kararli
Mark Kontny
Srikonda Sastry
Janaki Nyshadham
Arthur Pagliero Jr
Original Assignee
Yamanouchi Pharma Tech Inc
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharma Tech Inc, Pharmacia Corp filed Critical Yamanouchi Pharma Tech Inc
Publication of AR030382A1 publication Critical patent/AR030382A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe un proceso para preparar una composicion oral de fusion rápida de una droga inhibidora selectiva de cilooxigensasa-2, donde dicho proceso comprende (a) un paso de granulacion humeda de la droga, junto con un agente aglutinante que comprende un sacárido de alta moldeabilidad, y (b) un paso que consiste en mezclar un sacárido de baja moldeabilidad con la droga donde los pasos anteriormente mencionados (a) y (b) se llevan a cabo en cualquier orden o simultáneamente para causar la formacion de gránulos. El proceso opcionalmente incorpora medios para inhibir la aglomeracion de la droga, por ejemplo la adicion de un agente de humedecimiento. Opcionalmente el proceso comprende además (c) un paso de mezclar los gránulos con por lo menos uno de un lubricante, un agente edulcorante y un agente saborizante para hacer una mezcla para formar tabletas, y (d) un paso de compresion de la mezcla para formar las tabletas orales de fusion rápida. También se proporciona una composicion preparada mediante un proceso con esas características.
ARP010103961A 2000-08-18 2001-08-17 Formulacion oral de un inhibidor de ciclooxigenasa-2 de fusion rapida AR030382A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22634900P 2000-08-18 2000-08-18

Publications (1)

Publication Number Publication Date
AR030382A1 true AR030382A1 (es) 2003-08-20

Family

ID=37515865

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103961A AR030382A1 (es) 2000-08-18 2001-08-17 Formulacion oral de un inhibidor de ciclooxigenasa-2 de fusion rapida

Country Status (4)

Country Link
US (1) US20020119193A1 (es)
AR (1) AR030382A1 (es)
PE (1) PE20020322A1 (es)
TW (1) TWI256305B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19940740A1 (de) * 1999-08-31 2001-03-01 Gruenenthal Gmbh Pharmazeutische Salze
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
AU2003213719A1 (en) 2002-03-01 2003-09-16 Regents Of The University Of Michigan Multiple-component solid phases containing at least one active pharmaceutical ingredient
MXPA05000232A (es) * 2002-06-21 2005-06-17 Transform Pharmaceuticals Inc Composiciones farmaceuticas con disolucion mejorada.
AU2003267231A1 (en) * 2002-09-20 2004-04-08 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
RS20050390A (sr) * 2002-11-26 2008-04-04 Boehringer Ingelheim Pharma Gmbh. & Co.Kg., Farmaceutska kompozicija koja obuhvata ltb4 antagonist i koks-2 inhibitor ili kombinovani koks1/2 inhibitor
GB0228465D0 (en) * 2002-12-06 2003-01-08 Univ Belfast A method of treating disease
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
AT413944B (de) * 2003-05-27 2006-07-15 Binder Eva Dkfm Verwendung von oxicam-verbindungen
CA2542277A1 (en) * 2003-10-21 2005-05-12 Pharmacia Corporation Method for the treatment or prevention of respiratory inflammation with a cyclooxygenase-2 inhibitor in combination with a phosphodiesterase 4 inhibitor and compositions therewith
US20050113410A1 (en) * 2003-11-03 2005-05-26 Mark Tawa Pharmaceutical salts of zafirlukast
AU2005238220A1 (en) * 2004-04-29 2005-11-10 Binder, Eva Enantiomer-pure hexahydro- pyrrolocyclopenta- pyridine derivatives
EP1765296A2 (en) * 2004-06-30 2007-03-28 Albemarle Corporation High ibuprofen content granules and their preparation and use
EP1808163A1 (en) * 2005-12-22 2007-07-18 Teva Pharmaceutical Industries Ltd. Compressed solid dosage forms with drugs of low solubility and process for making the same
US20070148245A1 (en) * 2005-12-22 2007-06-28 Ilan Zalit Compressed solid dosage forms with drugs of low solubility and process for making the same
WO2007073389A1 (en) * 2005-12-22 2007-06-28 Teva Pharmaceutical Industries Ltd. Compressed solid dosage forms with drugs of low solubility and process for making the same
BRPI0717008A2 (pt) * 2006-09-01 2014-01-21 Usv Ltd Processo para o preparo de cloridrato de sevelamer e formulação do mesmo
US7964182B2 (en) * 2006-09-01 2011-06-21 USV, Ltd Pharmaceutical compositions comprising phosphate-binding polymer
MX2010003720A (es) * 2007-10-08 2010-10-20 Intrexon Corp Celulas dendriticas creadas por ingenieria genetica y usos para el tratamiento de cancer.
RU2011134847A (ru) * 2009-01-22 2013-02-27 Юсв Лимитед Фармацевтические композиции, содержащие фосфатсвязывающий полимер
CN104027319A (zh) * 2014-06-25 2014-09-10 万特制药(海南)有限公司 一种塞来昔布分散片及其制备方法
US10350171B2 (en) 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same
CN108057025A (zh) * 2017-12-08 2018-05-22 佛山市弘泰药物研发有限公司 一种依托考昔口崩片及其制备方法
CN111407733A (zh) * 2020-03-19 2020-07-14 大桐制药（中国）有限责任公司 一种塞莱昔布片剂的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6573290B1 (en) * 1999-05-17 2003-06-03 Ilex Oncology, Inc. DFMO and celecoxib in combination for cancer chemoprevention and therapy
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6964978B2 (en) * 1999-12-08 2005-11-15 Pharmacia Corporation Solid-state form of celecoxib having enhanced bioavailability

Also Published As

Publication number Publication date
PE20020322A1 (es) 2002-05-10
US20020119193A1 (en) 2002-08-29
TWI256305B (en) 2006-06-11

Similar Documents

Publication Publication Date Title
AR030382A1 (es) Formulacion oral de un inhibidor de ciclooxigenasa-2 de fusion rapida
WO2002015885A3 (en) Oral fast-melt formulation of a cyclooxygenase-2 inhibitor
UY26306A1 (es) Composición para la dosificación oral, de disolución instantanea
GT200200125A (es) Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco
BRPI0113286B8 (pt) pirazóis substituídos e composição farmacêutica compreendendo os mesmos.
WO2004032905A8 (en) Gabapentin tablets and methods for their preparation
DK1299108T3 (da) Parasiticidt præparat samt fremgangsmåde til fremstilling af dette præparat
KR850007559A (ko) 조절 펩타이드의 삽입식 제형
DE69942154D1 (de) Medikamenthaltige zusammensetzung in aerosolform
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
CR9292A (es) Comprimidos con dispersion mejorada de la sustancia farmacologica
PL361452A1 (en) Compositions containing sustained-release fine grains for tablets quickly disintegrable in the oral cavity and process for producing the same
PL357924A1 (en) Composition for peroxidisingly colouring creatinefibre, containing etherocarboxylic acid, oxyalkylenated polymer capable to form associates and non-saturated fatty acid
MXPA03000276A (es) Nueva formulacion en aerosol que contiene una molecula fluorada polar.
DE69001535D1 (de) Brausendes nagelmittel.
NL8200626A (nl) Werkwijze voor de bereiding van bruisende farmaceutische preparaten.
ES2173545T3 (es) Composicion parasiticida inyectable de larga accion y procedimiento para prepararla.
ES2124222T3 (es) Agentes edulcorantes de clorodesoxiazucar estabilizados en forma solida y procedimientos para su preparacion.
AR052787A1 (es) Proceso para preparar formulaciones de sustancias activas lipofilicas mediante liofilizacion por atomizacion
HUP0101822A2 (hu) Pezsegő kompozíciók és eljárás az előállításukra
WO2003061557A3 (en) Levothyroxine pharmaceutical compositions, methods of making and methods of administration
AR031206A1 (es) Sal de perborato expandida, su uso y metodo de produccion
AR041334A1 (es) Procedimiento de preparacion de composiciones de detergente en gel
RU99116432A (ru) Способ иммобилизации физиологически активных соединений
BG66112B1 (bg) Подобрени фармацевтични състави

Legal Events

Date Code Title Description
FB Suspension of granting procedure